Literature DB >> 10838085

The alpha2 and alpha5 integrin genes: identification of transcription factors that regulate promoter activity in epidermal keratinocytes.

A L Corbi1, U B Jensen, F M Watt.   

Abstract

We analysed the activity of the proximal promoters of the alpha2 and alpha5 integrin genes in human keratinocytes. An AP-1 site, found in the alpha5 but not the alpha2 promoter, bound c-Jun/c-Fos dimers and contributed strongly to promoter activity. Both promoters had a CCAAT/enhancer binding protein (C/EBP) binding site: the alpha5 C/EBP element enhanced activity, while the alpha2 site was a negative regulatory element. C/EBP overexpression repressed the activity of both promoters, but the effect was independent of occupancy of the identified C/EBP binding sites, suggesting interactions with additional transcription factors. We propose that upregulation of C/EBPs contributes to the inhibition of integrin transcription during keratinocyte terminal differentiation, while AP-1 factors play a role in the selective induction of the alpha5 gene during wound healing.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10838085     DOI: 10.1016/s0014-5793(00)01591-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

Review 1.  Cell-extracellular matrix interactions in normal and diseased skin.

Authors:  Fiona M Watt; Hironobu Fujiwara
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-04-01       Impact factor: 10.005

2.  Steroid receptor coactivator-1 upregulates integrin α₅ expression to promote breast cancer cell adhesion and migration.

Authors:  Li Qin; Xian Chen; Yelin Wu; Zhen Feng; Tao He; Li Wang; Lan Liao; Jianming Xu
Journal:  Cancer Res       Date:  2011-02-22       Impact factor: 12.701

3.  Analysis of methamphetamine-induced changes in the expression of integrin family members in the cortex of wild-type and c-fos knockout mice.

Authors:  Elizabeth S. Betts; Irina N. Krasnova; Michael T. McCoy; Bruce Ladenheim; Jean Lud Cadet
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

4.  Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation.

Authors:  Jodi A McKenzie; Tong Liu; Agnessa G Goodson; Douglas Grossman
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

5.  Dissection of a complex enhancer element: maintenance of keratinocyte specificity but loss of differentiation specificity.

Authors:  Charles K Kaufman; Satrajit Sinha; Diana Bolotin; Jie Fan; Elaine Fuchs
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

Review 6.  Glycogen synthase kinase 3 beta: can it be a target for oral cancer.

Authors:  Rajakishore Mishra
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

7.  N-terminal and C-terminal heparin-binding domain polypeptides derived from fibronectin reduce adhesion and invasion of liver cancer cells.

Authors:  Nan-Hong Tang; Yan-Lin Chen; Xiao-Qian Wang; Xiu-Jin Li; Yong Wu; Qi-Lian Zou; Yuan-Zhong Chen
Journal:  BMC Cancer       Date:  2010-10-13       Impact factor: 4.430

8.  Human papillomavirus type 8 E2 protein unravels JunB/Fra-1 as an activator of the beta4-integrin gene in human keratinocytes.

Authors:  Monika Oldak; Radoslaw B Maksym; Tanya Sperling; Moshe Yaniv; Hans Smola; Herbert J Pfister; Jacek Malejczyk; Sigrun Smola
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

9.  Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin.

Authors:  L Damiano; K M Stewart; N Cohet; J K Mouw; J N Lakins; J Debnath; D Reisman; J A Nickerson; A N Imbalzano; V M Weaver
Journal:  Oncogene       Date:  2013-06-17       Impact factor: 9.867

10.  C/EBPbeta represses p53 to promote cell survival downstream of DNA damage independent of oncogenic Ras and p19(Arf).

Authors:  S J Ewing; S Zhu; F Zhu; J S House; R C Smart
Journal:  Cell Death Differ       Date:  2008-07-18       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.